Adial Pharmaceuticals Warrant
ADILW
ADILW was delisted on the 27th of July, 2023.
5 hedge funds and large institutions have $499 invested in Adial Pharmaceuticals Warrant in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 0 reducing their positions, and closing their positions.
150% more funds holding
Funds holding: 2 → 5 (+3)
73% less capital invested
Capital invested by funds: $1.88K → $499 (-$1.38K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$341 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$148 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Ameriprise
Minneapolis,
Minnesota
| $200 | – | – | – |
|
|
WAM
2
Wolverine Asset Management
Chicago,
Illinois
| $88 | – | – | – |
|
|
GS
3
GTS Securities
New York
| $86 | +$327 | +14,401 | New |
|
|
4
Wells Fargo
San Francisco,
California
| $86 | +$341 | +15,000 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $39 | +$148 | +6,534 | New |
|
ADILW Hedge Fund Activity: Q2 2023 in Review
5 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals Warrant (ADILW) for Q2 2023, worth a combined $499 — down 73% from $1.88K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ADILW positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Wells Fargo, opening a new position worth an estimated $341.
- 5 institutional investors held Adial Pharmaceuticals Warrant (ADILW) as of Q2 2023, up from 2 in Q1 2023.
- Funds reported $499 of Adial Pharmaceuticals Warrant stock for Q2 2023, down 73% quarter-over-quarter.
- 3 funds opened new Adial Pharmaceuticals Warrant positions in Q2 2023 and 0 closed out, a net change of +3 holders.
- The largest Adial Pharmaceuticals Warrant buyer in Q2 2023 was Wells Fargo, an estimated $341 added.
Based on aggregated 13F filings for Q2 2023.